Prostate Cancer - Pipeline Review, H2: Market Size 2014

1. Prostate Cancer - Pipeline Review, H2 2014 (Type, Mode of action, Crop Type and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020 • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com Published on : Oct 2014

2. Report Overview Research Beam adds a report titled “Prostate Cancer - Pipeline Review, H2 2014” that provides latest market trends and opportunities. The report offers detailed analysis of the Prostate Cancer. Summary Global Markets Direct’s, ‘Prostate Cancer - Pipeline Review, H2 2014’, provides an overview of the Prostate Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects. Get Full Details On: http://www.researchbeam.com/prostate-cancer-pipeline-review-h2-2014-market

3. Report Overview lobal Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

4. Report Overview Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Prostate Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Prostate Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects -A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects

5. Report Overview Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

6. Table of Contents Introduction 11 Prostate Cancer Overview 12 Therapeutics Development 13 Prostate Cancer - Therapeutics under Development by Companies 15 Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 36 Prostate Cancer - Pipeline Products Glance 41 Prostate Cancer - Products under Development by Companies 45 Prostate Cancer - Products under Investigation by Universities/Institutes 71 Prostate Cancer - Companies Involved in Therapeutics Development 77 Prostate Cancer - Therapeutics Assessment 313 Prostate Cancer - Recent Pipeline Updates 1039 Prostate Cancer - Dormant Projects 1283 Enquire About Report: http://www.researchbeam.com/prostate-cancer-pipeline-review-h2-2014-market/enquire-about-report

7. List of Tables Number of Products under Development for Prostate Cancer, H2 2014 64 Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2014 65 Number of Products under Development by Companies, H2 2014 67 Number of Products under Development by Companies, H2 2014 (Contd..1) 68 Number of Products under Development by Companies, H2 2014 (Contd..2) 69 Number of Products under Development by Companies, H2 2014 (Contd..3) 70 Number of Products under Development by Companies, H2 2014 (Contd..4) 71 Number of Products under Development by Companies, H2 2014 (Contd..5) 72 Number of Products under Development by Companies, H2 2014 (Contd..6) 73 Number of Products under Development by Companies, H2 2014 (Contd..7) 74 Number of Products under Development by Companies, H2 2014 (Contd..8) 75 Number of Products under Development by Companies, H2 2014 (Contd..9) 76 Number of Products under Development by Companies, H2 2014 (Contd..10) 77 Number of Products under Development by Companies, H2 2014 (Contd..11) 78 Number of Products under Development by Companies, H2 2014 (Contd..12) 79

8. List of Tables Comparative Analysis by Late Stage Development, H2 2014 92 Comparative Analysis by Clinical Stage Development, H2 2014 93 Comparative Analysis by Early Stage Development, H2 2014 94 Comparative Analysis by Unknown Stage Development, H2 2014 95 Products under Development by Companies, H2 2014 96 Products under Development by Companies, H2 2014 (Contd..1) 97 Products under Development by Companies, H2 2014 (Contd..2) 98 Products under Development by Companies, H2 2014 (Contd..3) 99 Products under Development by Companies, H2 2014 (Contd..4) 100 Products under Development by Companies, H2 2014 (Contd..5) 101 Products under Development by Companies, H2 2014 (Contd..6) 102 Products under Development by Companies, H2 2014 (Contd..7) 103 Products under Development by Companies, H2 2014 (Contd..8) 104 Products under Development by Companies, H2 2014 (Contd..9) 105 Products under Development by Companies, H2 2014 (Contd..10) 106

9. List of Figures Number of Products under Development for Prostate Cancer, H2 2014 64 Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2014 65 Number of Products under Development by Companies, H2 2014 66 Number of Products under Investigation by Universities/Institutes, H2 2014 87 Comparative Analysis by Late Stage Development, H2 2014 92 Comparative Analysis by Clinical Stage Development, H2 2014 93 Comparative Analysis by Early Stage Products, H2 2014 94 Assessment by Monotherapy Products, H2 2014 364 Assessment by Combination Products, H2 2014 365 Number of Products by Top 10 Target, H2 2014 366 Number of Products by Stage and Top 10 Target, H2 2014 367 Number of Products by Top 10 Mechanism of Action, H2 2014 376 Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 377 Number of Products by Top 10 Route of Administration, H2 2014 387 Number of Products by Stage and Top 10 Route of Administration, H2 2014 388

10. Similar Market Studies • Published Reports • Neos Therapeutics, Inc. - Product Pipeline Review - 2014 • http://www.researchbeam.com/neos-therapeutics-inc-product-pipeline-review-2014-market • CureVac GmbH - Product Pipeline Review - 2014 • http://www.researchbeam.com/curevac-gmbh-product-pipeline-review-2014-market • arGEN-X BV - Product Pipeline Review - 2014 • http://www.researchbeam.com/argen-x-bv-product-pipeline-review-2014-market

11. FOR MORE DETAILS Visit us at : http://www.researchbeam.com/ Stay With Us: 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com